entacapone vs Opicapone

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: COMT · full Parkinson's Disease pipeline

entacapone · Comtess

Marketed by Orion Corporation and partners

Approved in Parkinson's Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: February 2027 · NCT04246437 (registry estimate)

No aligned efficacy figure on record for this race.

Opicapone · Ongentys

Marketed by Amneal Pharmaceuticals and partners

Approved in Parkinson's Diseasesmall molecule
Partial signal

NCT01568073 · Phase 3 · completed

BIPARK-1 was a randomized, double-blind, placebo- and entacapone-controlled Phase 3 trial in 600 patients with Parkinson disease and end-of-dose motor fluctuations. The primary endpoint was the change in absolute OFF-time, tested for each opicapone dose first for superiority to placebo and then for non-inferiority to entacapone. Opicapone 50 mg was superior to placebo (-60.8 minutes, p=0.0015) and non-inferior to entacapone. The 5 mg and 25 mg doses did not differ significantly from placebo. With one dose positive and two not, the result is mixed. Source: Ferreira et al., Lancet Neurol 2016.

Reported efficacy

Change from baseline (Visit 2) to the end of the double-blind period (Visit 9) in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III total score (Up to 24 weeks); Change from open-label baseline (Visit 9) to the end of the open-label period (Visit 15) in MDS-UPDRS Part IV total score. (Up to 1-year.): Change in MDS-UPDRS Part III total score from baseline to Week 24: -6.5 opicapone vs -4.3 placebo; difference -2.2 (95% CI -3.9, -0.5) favoring opicapone, p=0.010 (met)

Result source: NCT04978597

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointentacaponeOpicapone
OFF time, change—Not posted · NCT00134966—Not posted · NCT04978597
ON time without troublesome dyskinesia, change—Not posted · NCT00134966—Not posted · NCT04978597
UPDRS Part III, change-3.7 vs -1.8vs Carbidopa/Levodopawk 4 · n 161NCT00219284
3 other results
  • -3.6 vs -3.7 wk 8 · n 146 · Phase 4 · secondary NCT00219284
  • -3.6 vs -3.3 n 176 · Phase 4 · secondary NCT00219284
  • -4 vs -1.4 wk 12 · n 35 · Phase 4 · secondary NCT00391898
—Not posted · NCT04978597
MDS-UPDRS Part II, change—Not posted · NCT00134966—Not posted · NCT04978597

OFF time, change

entacapone
—Not posted · NCT00134966
Opicapone
—Not posted · NCT04978597

ON time without troublesome dyskinesia, change

entacapone
—Not posted · NCT00134966
Opicapone
—Not posted · NCT04978597

UPDRS Part III, change

entacapone
-3.7 vs -1.8vs Carbidopa/Levodopawk 4 · n 161NCT00219284
3 other results
  • -3.6 vs -3.7 wk 8 · n 146 · Phase 4 · secondary NCT00219284
  • -3.6 vs -3.3 n 176 · Phase 4 · secondary NCT00219284
  • -4 vs -1.4 wk 12 · n 35 · Phase 4 · secondary NCT00391898
Opicapone
—Not posted · NCT04978597

MDS-UPDRS Part II, change

entacapone
—Not posted · NCT00134966
Opicapone
—Not posted · NCT04978597
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. entacapone: 4 of 4 rows · Opicapone: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricentacaponeOpicapone
Dropout rate
24.4%a
NCT00219284 · Phase 4 · registry result, not featured evidence
show 2 more results
23.9%
NCT00391898 · Phase 4 · registry result, not featured evidence
—
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
7.8%50 mgb
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
show 57 more results
9.2%25 mg
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
9.8%5 mg
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
16.9%50 mg
NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3
8.5%25 mg
NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3
17.2%50 mg
NCT04986982 · Phase 4 · registry result, not featured evidence
10%5 mg
NCT01568047 · Phase 2 · registry result, not featured evidence
10%30 mg
NCT01568047 · Phase 2 · registry result, not featured evidence
10%15 mg
NCT01568047 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01568034 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01568034 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01568034 · Phase 2 · registry result, not featured evidence
—Opicapone Alone
NCT02305017 · Phase 1 · registry result, not featured evidence · monotherapy
—Opicapone Plus Paracetamol
NCT02305017 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
0%50 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
7.1%25 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
7.7%5 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
0%
NCT02169427 · Phase 1 · registry result, not featured evidence
—
NCT01536366 · Phase 1 · registry result, not featured evidence · combination
0%
NCT01515891 · Phase 1 · registry result, not featured evidence
—BIA 9-1067 1h Before Rasagiline
NCT01532141 · Phase 1 · registry result, not featured evidence · combination
—BIA 9-1067 Alone
NCT01532141 · Phase 1 · registry result, not featured evidence · monotherapy
—BIA 9-1067 Concomitant Rasagiline
NCT01532141 · Phase 1 · registry result, not featured evidence · combination
—Rasagiline 1 h After BIA 9-1067
NCT01532128 · Phase 1 · registry result, not featured evidence · combination
—Rasagiline Concomitant BIA 9-1067
NCT01532128 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02169414 · Phase 1 · registry result, not featured evidence
5.3%5 mg
NCT02169414 · Phase 1 · registry result, not featured evidence
5.3%15 mg
NCT02169414 · Phase 1 · registry result, not featured evidence
—50 mg
NCT01533077 · Phase 1 · registry result, not featured evidence
—50 mg + 100/25 mg
NCT01533077 · Phase 1 · registry result, not featured evidence · combination
—50 mg + 100/25 mg
NCT01533077 · Phase 1 · registry result, not featured evidence · combination
—
NCT02169440 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02169466 · Phase 1 · registry result, not featured evidence
—25 mg
NCT02169466 · Phase 1 · registry result, not featured evidence
—100 mg
NCT02169466 · Phase 1 · registry result, not featured evidence
0%50 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
0%1200 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
0%800 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
0%400 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
0%200 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
0%100 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
—30 mg once daily
NCT02092168 · Phase 1 · registry result, not featured evidence
—30 mg once daily
NCT02092168 · Phase 1 · registry result, not featured evidence
—50 mg
NCT02169479 · Phase 1 · registry result, not featured evidence
—25 mg
NCT02169479 · Phase 1 · registry result, not featured evidence
—100 mg
NCT02169479 · Phase 1 · registry result, not featured evidence
—50 mg
NCT02169895 · Phase 1 · registry result, not featured evidence
—25 mg
NCT02169895 · Phase 1 · registry result, not featured evidence
—100 mg
NCT02169895 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT02071810 · Phase 1 · registry result, not featured evidence
14.3%30 mg
NCT02071810 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT02071810 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT02071810 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
14.4%a
NCT00219284 · Phase 4 · registry result, not featured evidence
show 2 more results
6.5%
NCT00391898 · Phase 4 · registry result, not featured evidence
—
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
—50 mgb
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
show 57 more results
—25 mg
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
—5 mg
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
—50 mg
NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3
—25 mg
NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3
6.3%50 mg
NCT04986982 · Phase 4 · registry result, not featured evidence
0%5 mg
NCT01568047 · Phase 2 · registry result, not featured evidence
10%30 mg
NCT01568047 · Phase 2 · registry result, not featured evidence
10%15 mg
NCT01568047 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01568034 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01568034 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01568034 · Phase 2 · registry result, not featured evidence
—Opicapone Alone
NCT02305017 · Phase 1 · registry result, not featured evidence · monotherapy
—Opicapone Plus Paracetamol
NCT02305017 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
—50 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
—25 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
—25 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
—5 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
—5 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
—
NCT02169427 · Phase 1 · registry result, not featured evidence
—
NCT01536366 · Phase 1 · registry result, not featured evidence · combination
—
NCT01515891 · Phase 1 · registry result, not featured evidence
—BIA 9-1067 1h Before Rasagiline
NCT01532141 · Phase 1 · registry result, not featured evidence · combination
—BIA 9-1067 Alone
NCT01532141 · Phase 1 · registry result, not featured evidence · monotherapy
—BIA 9-1067 Concomitant Rasagiline
NCT01532141 · Phase 1 · registry result, not featured evidence · combination
—Rasagiline 1 h After BIA 9-1067
NCT01532128 · Phase 1 · registry result, not featured evidence · combination
—Rasagiline Concomitant BIA 9-1067
NCT01532128 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02169414 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT02169414 · Phase 1 · registry result, not featured evidence
5.3%15 mg
NCT02169414 · Phase 1 · registry result, not featured evidence
—50 mg
NCT01533077 · Phase 1 · registry result, not featured evidence
—50 mg + 100/25 mg
NCT01533077 · Phase 1 · registry result, not featured evidence · combination
—50 mg + 100/25 mg
NCT01533077 · Phase 1 · registry result, not featured evidence · combination
—
NCT02169440 · Phase 1 · registry result, not featured evidence · combination
—50 mg
NCT02169466 · Phase 1 · registry result, not featured evidence
—25 mg
NCT02169466 · Phase 1 · registry result, not featured evidence
—100 mg
NCT02169466 · Phase 1 · registry result, not featured evidence
—50 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
—25 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
—1200 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
—800 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
—400 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
—200 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
—100 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
—10 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
—30 mg once daily
NCT02092168 · Phase 1 · registry result, not featured evidence
—30 mg once daily
NCT02092168 · Phase 1 · registry result, not featured evidence
—50 mg
NCT02169479 · Phase 1 · registry result, not featured evidence
—25 mg
NCT02169479 · Phase 1 · registry result, not featured evidence
—100 mg
NCT02169479 · Phase 1 · registry result, not featured evidence
—50 mg
NCT02169895 · Phase 1 · registry result, not featured evidence
—25 mg
NCT02169895 · Phase 1 · registry result, not featured evidence
—100 mg
NCT02169895 · Phase 1 · registry result, not featured evidence
—5 mg
NCT02071810 · Phase 1 · registry result, not featured evidence
—30 mg
NCT02071810 · Phase 1 · registry result, not featured evidence
—20 mg
NCT02071810 · Phase 1 · registry result, not featured evidence
—10 mg
NCT02071810 · Phase 1 · registry result, not featured evidence
Serious AEs
4.4%a
NCT00219284 · Phase 4 · registry result, not featured evidence
show 2 more results
2.2%
NCT00391898 · Phase 4 · registry result, not featured evidence
0%
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
3.5%50 mgb
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
show 57 more results
0.8%25 mg
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
3.3%5 mg
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
6%50 mg
NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3
3.2%25 mg
NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3
6.3%50 mg
NCT04986982 · Phase 4 · registry result, not featured evidence
0%5 mg
NCT01568047 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT01568047 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT01568047 · Phase 2 · registry result, not featured evidence
0%50 mg
NCT01568034 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT01568034 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT01568034 · Phase 2 · registry result, not featured evidence
0%Opicapone Alone
NCT02305017 · Phase 1 · registry result, not featured evidence · monotherapy
0%Opicapone Plus Paracetamol
NCT02305017 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
0%50 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT01520987 · Phase 1 · registry result, not featured evidence
0%
NCT02169427 · Phase 1 · registry result, not featured evidence
0%
NCT01536366 · Phase 1 · registry result, not featured evidence · combination
0%
NCT01515891 · Phase 1 · registry result, not featured evidence
0%BIA 9-1067 1h Before Rasagiline
NCT01532141 · Phase 1 · registry result, not featured evidence · combination
0%BIA 9-1067 Alone
NCT01532141 · Phase 1 · registry result, not featured evidence · monotherapy
0%BIA 9-1067 Concomitant Rasagiline
NCT01532141 · Phase 1 · registry result, not featured evidence · combination
0%Rasagiline 1 h After BIA 9-1067
NCT01532128 · Phase 1 · registry result, not featured evidence · combination
0%Rasagiline Concomitant BIA 9-1067
NCT01532128 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02169414 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT02169414 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT02169414 · Phase 1 · registry result, not featured evidence
0%50 mg
NCT01533077 · Phase 1 · registry result, not featured evidence
0%50 mg + 100/25 mg
NCT01533077 · Phase 1 · registry result, not featured evidence · combination
0%50 mg + 100/25 mg
NCT01533077 · Phase 1 · registry result, not featured evidence · combination
0%
NCT02169440 · Phase 1 · registry result, not featured evidence · combination
0%50 mg
NCT02169466 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT02169466 · Phase 1 · registry result, not featured evidence
0%100 mg
NCT02169466 · Phase 1 · registry result, not featured evidence
0%50 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
0%1200 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
0%800 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
0%400 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
0%200 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
0%100 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT01520727 · Phase 1 · registry result, not featured evidence
0%30 mg once daily
NCT02092168 · Phase 1 · registry result, not featured evidence
0%30 mg once daily
NCT02092168 · Phase 1 · registry result, not featured evidence
0%50 mg
NCT02169479 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT02169479 · Phase 1 · registry result, not featured evidence
0%100 mg
NCT02169479 · Phase 1 · registry result, not featured evidence
0%50 mg
NCT02169895 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT02169895 · Phase 1 · registry result, not featured evidence
0%100 mg
NCT02169895 · Phase 1 · registry result, not featured evidence
0%5 mg
NCT02071810 · Phase 1 · registry result, not featured evidence
0%30 mg
NCT02071810 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT02071810 · Phase 1 · registry result, not featured evidence
0%10 mg
NCT02071810 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
nausea 17.2%
diarrhoea 16.1%
dizziness 8.9%
NCT00219284 · Phase 4 · registry result, not featured evidence
show 2 more results
dyskinesia 15.6%
anxiety 11.1%
retching 6.7%
NCT00391898 · Phase 4 · registry result, not featured evidence
back pain 12.5% (placebo 0%)
pain in extremity 12.5% (placebo 9.1%)
abdominal pain lower 0% (placebo 0%)
NCT01883505 · Phase 2 · registry result, not featured evidence · combination
50 mgb
dyskinesia 15.7% (placebo 4.1%)
constipation 6.1% (placebo 2.5%)
insomnia 6.1% (placebo 0.8%)
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
show 57 more results
25 mg
dyskinesia 7.6% (placebo 4.1%)
insomnia 5.9% (placebo 0.8%)
dizziness 5% (placebo 0.8%)
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
5 mg
dyskinesia 13.9% (placebo 4.1%)
back pain 3.3% (placebo 5%)
constipation 3.3% (placebo 2.5%)
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
50 mg
dyskinesia 24% (placebo 8.1%)
blood cpk increased 8% (placebo 3.7%)
constipation 6.7% (placebo 1.5%)
NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3
25 mg
dyskinesia 24% (placebo 8.1%)
dry mouth 10.4% (placebo 0.7%)
constipation 9.6% (placebo 1.5%)
NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3
50 mg
nausea 10.9% (placebo 7.9%)
anxiety 9.4% (placebo 3.2%)
constipation 7.8% (placebo 1.6%)
NCT04986982 · Phase 4 · registry result, not featured evidence
5 mg
dizziness 10% (placebo 10%)
fatigue 10% (placebo 0%)
hyperhidrosis 10% (placebo 0%)
NCT01568047 · Phase 2 · registry result, not featured evidence
30 mg
abdominal pain upper 10% (placebo 0%)
diarrhoea 10% (placebo 0%)
dyskinesia 10% (placebo 0%)
NCT01568047 · Phase 2 · registry result, not featured evidence
15 mg
bradyphrenia 10% (placebo 0%)
depression 10% (placebo 0%)
dizziness 10% (placebo 10%)
NCT01568047 · Phase 2 · registry result, not featured evidence
50 mg
blood pressure increased 10% (placebo 0%)
eosinophil percentage increased 10% (placebo 11.1%)
hypertension 10% (placebo 0%)
NCT01568034 · Phase 2 · registry result, not featured evidence
25 mg
anaemia 10% (placebo 0%)
constipation 10% (placebo 0%)
headache 10% (placebo 0%)
NCT01568034 · Phase 2 · registry result, not featured evidence
100 mg
eosinophil percentage increased 10% (placebo 11.1%)
haematuria 10% (placebo 0%)
hypertension 10% (placebo 0%)
NCT01568034 · Phase 2 · registry result, not featured evidence
tooth abscess 3.6%
nasopharyngitis 0%
NCT02305017 · Phase 1 · registry result, not featured evidence · monotherapy
nasopharyngitis 3.6%
tooth abscess 0%
NCT02305017 · Phase 1 · registry result, not featured evidence · combination
50 mg
arthropod bite 9.1% (placebo 6.7%)
back pain 9.1% (placebo 0%)
dizziness 9.1% (placebo 6.7%)
NCT01520987 · Phase 1 · registry result, not featured evidence
50 mg
vessel puncture site haematoma 25% (placebo 13.3%)
tension headache 16.7% (placebo 0%)
back pain 8.3% (placebo 0%)
NCT01520987 · Phase 1 · registry result, not featured evidence
25 mg
vessel puncture site haematoma 25% (placebo 13.3%)
hordeolum 8.3% (placebo 6.7%)
myalgia 8.3% (placebo 0%)
NCT01520987 · Phase 1 · registry result, not featured evidence
25 mg
vessel puncture site haematoma 14.3% (placebo 13.3%)
dizziness postural 7.1% (placebo 0%)
energy increased 7.1% (placebo 0%)
NCT01520987 · Phase 1 · registry result, not featured evidence
5 mg
vessel puncture site haematoma 30.8% (placebo 13.3%)
nausea 23.1% (placebo 6.7%)
dizziness 7.7% (placebo 6.7%)
NCT01520987 · Phase 1 · registry result, not featured evidence
5 mg
headache 14.3% (placebo 6.7%)
arthropod bite 7.1% (placebo 6.7%)
contusion 7.1% (placebo 0%)
NCT01520987 · Phase 1 · registry result, not featured evidence
somnolence 33.3%
frequent bowel movements 16.7%
headache 16.7%
NCT02169427 · Phase 1 · registry result, not featured evidence
alanine aminotransferase increased 4.2%
aspartate aminotransferase increased 4.2%
fall 4.2%
NCT01536366 · Phase 1 · registry result, not featured evidence · combination
headache 50%
tiredness 50%
flatulence 25%
NCT01515891 · Phase 1 · registry result, not featured evidence
nasopharyngitis 8.3%
back pain 4.2%
headache 4.2%
NCT01532141 · Phase 1 · registry result, not featured evidence · combination
headache 24%
bronchitis 4%
chest discomfort 4%
NCT01532141 · Phase 1 · registry result, not featured evidence · monotherapy
headache 4.2%
nasopharyngitis 4.2%
neck pain 4.2%
NCT01532141 · Phase 1 · registry result, not featured evidence · combination
blood creatine phosphokinase increased 4.2%
headache 4.2%
sciatica 4.2%
NCT01532128 · Phase 1 · registry result, not featured evidence · combination
diarrhoea 4.2%
influenza like illness 4.2%
sciatica 4.2%
NCT01532128 · Phase 1 · registry result, not featured evidence · combination
50 mg
asthenia 5.6% (placebo 0%)
dizziness 5.6% (placebo 0%)
headache 5.6% (placebo 5.6%)
NCT02169414 · Phase 1 · registry result, not featured evidence
5 mg
headache 26.3% (placebo 5.6%)
diarrhoea 10.5% (placebo 0%)
arthralgia 5.3% (placebo 0%)
NCT02169414 · Phase 1 · registry result, not featured evidence
15 mg
nausea 21.1% (placebo 0%)
back pain 5.3% (placebo 0%)
cystitis 5.3% (placebo 0%)
NCT02169414 · Phase 1 · registry result, not featured evidence
50 mg
somnolence 33.3%
headache 11.1%
blood pressure systolic increased 5.6%
NCT01533077 · Phase 1 · registry result, not featured evidence
50 mg + 100/25 mg
headache 25%
somnolence 25%
oropharyngeal pain 12.5%
NCT01533077 · Phase 1 · registry result, not featured evidence · combination
50 mg + 100/25 mg
somnolence 22.2%
headache 16.7%
rash 11.1%
NCT01533077 · Phase 1 · registry result, not featured evidence · combination
blood creatine phosphokinase increased 10%
decreased appetite 5%
dizziness 5%
NCT02169440 · Phase 1 · registry result, not featured evidence · combination
50 mg
blood creatine phosphokinase increased 9.1% (placebo 0%)
nasopharyngitis 4.5% (placebo 0%)
oral herpes 4.5% (placebo 0%)
NCT02169466 · Phase 1 · registry result, not featured evidence
25 mg
blood creatine phosphokinase increased 4.8% (placebo 0%)
respiratory tract infection 4.8% (placebo 0%)
depression 0% (placebo 4.8%)
NCT02169466 · Phase 1 · registry result, not featured evidence
100 mg
headache 4.5% (placebo 4.8%)
rash 4.5% (placebo 0%)
rhinorrhea 4.5% (placebo 0%)
NCT02169466 · Phase 1 · registry result, not featured evidence
50 mg
nasopharyngitis 16.7% (placebo 0%)
syncope vasovagal 16.7% (placebo 0%)
epistaxis 0% (placebo 0%)
NCT01520727 · Phase 1 · registry result, not featured evidence
25 mg
epistaxis 0% (placebo 0%)
gastroenteritis 0% (placebo 6.3%)
headache 0% (placebo 0%)
NCT01520727 · Phase 1 · registry result, not featured evidence
1200 mg
headache 16.7% (placebo 0%)
epistaxis 0% (placebo 0%)
gastroenteritis 0% (placebo 6.3%)
NCT01520727 · Phase 1 · registry result, not featured evidence
800 mg
epistaxis 0% (placebo 0%)
gastroenteritis 0% (placebo 6.3%)
headache 0% (placebo 0%)
NCT01520727 · Phase 1 · registry result, not featured evidence
400 mg
epistaxis 16.7% (placebo 0%)
gastroenteritis 0% (placebo 6.3%)
headache 0% (placebo 0%)
NCT01520727 · Phase 1 · registry result, not featured evidence
200 mg
headache 16.7% (placebo 0%)
epistaxis 0% (placebo 0%)
gastroenteritis 0% (placebo 6.3%)
NCT01520727 · Phase 1 · registry result, not featured evidence
100 mg
epistaxis 0% (placebo 0%)
gastroenteritis 0% (placebo 6.3%)
headache 0% (placebo 0%)
NCT01520727 · Phase 1 · registry result, not featured evidence
10 mg
epistaxis 0% (placebo 0%)
gastroenteritis 0% (placebo 6.3%)
headache 0% (placebo 0%)
NCT01520727 · Phase 1 · registry result, not featured evidence
30 mg once daily
headache 8.3%
pharyngolaryngeal pain 8.3%
bronchitis lymphangitis 0%
NCT02092168 · Phase 1 · registry result, not featured evidence
30 mg once daily
bronchitis lymphangitis 8.3%
influenza like illness 8.3%
pruritus 8.3%
NCT02092168 · Phase 1 · registry result, not featured evidence
50 mg
dizziness 18.8% (placebo 0%)
headache 12.5% (placebo 0%)
somnolence 12.5% (placebo 7.1%)
NCT02169479 · Phase 1 · registry result, not featured evidence
25 mg
somnolence 20% (placebo 7.1%)
headache 13.3% (placebo 0%)
nausea 13.3% (placebo 0%)
NCT02169479 · Phase 1 · registry result, not featured evidence
100 mg
blood creatine phosphokinase increased 13.3% (placebo 0%)
groin pain 6.7% (placebo 0%)
hematuria 6.7% (placebo 0%)
NCT02169479 · Phase 1 · registry result, not featured evidence
50 mg
somnolence 31.3% (placebo 12.5%)
insomnia 12.5% (placebo 0%)
nausea 12.5% (placebo 6.3%)
NCT02169895 · Phase 1 · registry result, not featured evidence
25 mg
ocular hyperaemia 18.8% (placebo 6.3%)
somnolence 18.8% (placebo 12.5%)
headache 12.5% (placebo 0%)
NCT02169895 · Phase 1 · registry result, not featured evidence
100 mg
somnolence 35.7% (placebo 12.5%)
cough 7.1% (placebo 6.3%)
dry mouth 7.1% (placebo 0%)
NCT02169895 · Phase 1 · registry result, not featured evidence
5 mg
headache 50% (placebo 0%)
muscle spasms 0% (placebo 0%)
orthostatic hypotension 0% (placebo 0%)
NCT02071810 · Phase 1 · registry result, not featured evidence
30 mg
headache 14.3% (placebo 0%)
muscle spasms 14.3% (placebo 0%)
vomiting 14.3% (placebo 0%)
NCT02071810 · Phase 1 · registry result, not featured evidence
20 mg
orthostatic hypotension 16.7% (placebo 0%)
headache 0% (placebo 0%)
muscle spasms 0% (placebo 0%)
NCT02071810 · Phase 1 · registry result, not featured evidence
10 mg
vomiting 16.7% (placebo 0%)
headache 0% (placebo 0%)
muscle spasms 0% (placebo 0%)
NCT02071810 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 53 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

entacapone

UPDRS Part III -3.7 vs -1.8 Carbidopa/Levodopa score @ 4wk
absolute change · score
NCT00219284 · Phase 4 · registry result, not featured evidence
show 3 more results
-3.6 vs -3.7 Carbidopa/Levodopa score @ 8wk
NCT00219284 · Phase 4 · registry result, not featured evidence
-3.6 vs -3.3 Carbidopa/Levodopa score
NCT00219284 · Phase 4 · registry result, not featured evidence
-4 vs -1.42 Levodopa/Carbidopa score @ 12wk
NCT00391898 · Phase 4 · registry result, not featured evidence
Pdqol -0.4 vs 1.1 Carbidopa/Levodopa score @ 4wk
absolute change · score
NCT00219284 · Phase 4 · registry result, not featured evidence
show 2 more results
-2.5 vs -1.1 Carbidopa/Levodopa score @ 8wk
NCT00219284 · Phase 4 · registry result, not featured evidence
-1.3 vs 0.2 Carbidopa/Levodopa score
NCT00219284 · Phase 4 · registry result, not featured evidence
PDQ-39 -1.7 vs 0.8 Carbidopa/Levodopa score @ 4wk
absolute change · score
NCT00219284 · Phase 4 · registry result, not featured evidence
show 3 more results
-5.8 vs -1.9 Carbidopa/Levodopa score @ 8wk
NCT00219284 · Phase 4 · registry result, not featured evidence
-2.8 vs 0.4 Carbidopa/Levodopa score
NCT00219284 · Phase 4 · registry result, not featured evidence
6.3 vs 0.8 Levodopa/Carbidopa score @ 12wk
NCT00391898 · Phase 4 · registry result, not featured evidence
UPDRS Part II ADL -2.5 vs -0.5 Levodopa/Carbidopa score @ 12wk
absolute change · score
NCT00391898 · Phase 4 · registry result, not featured evidence
UPDRS Part I -0.5 vs -0.2 Levodopa/Carbidopa score @ 12wk
absolute change · score
NCT00391898 · Phase 4 · registry result, not featured evidence
UPDRS Part IV -0.6 vs -0.1 Levodopa/Carbidopa score @ 12wk
absolute change · score
NCT00391898 · Phase 4 · registry result, not featured evidence

Opicapone

OFF Time Change -116.8 vs -56 placebo minutes @ 15wk50 mg
absolute change · minutes
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
show 4 more results
-124 vs -64.5 placebo minutes @ 14.5wk50 mg
NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3
-85.9 vs -56 placebo minutes @ 15wk25 mg
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
-102.8 vs -64.5 placebo minutes @ 14.5wk25 mg
NCT01227655 · Phase 3 · combination · Parkinson's Disease · phase 3
-91.3 vs -56 placebo minutes @ 15wk5 mg
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
UPDRS Total 31.5 vs 32.1 placebo score @ 15wk50 mg
absolute value · score
Endpoint (14 to 15 weeks)
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
show 2 more results
32 vs 32.1 placebo score @ 15wk25 mg
Endpoint (14 to 15 weeks)
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
31 vs 32.1 placebo score @ 15wk5 mg
Endpoint (14 to 15 weeks)
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
UPDRS Total -6.5 vs -5.6 placebo score @ 15wk50 mg
absolute change · score
Change from Baseline to Endpoint
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
show 2 more results
-7.6 vs -5.6 placebo score @ 15wk25 mg
Change from Baseline to Endpoint
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
-7.6 vs -5.6 placebo score @ 15wk5 mg
Change from Baseline to Endpoint
NCT01568073 · Phase 3 · combination · Parkinson's Disease · phase 3
KPPS Domain 3 -6.6 vs -5.9 placebo score @ 4.14wk50 mg
absolute change · score
Visit 4 (Day 29 (±2)) - Change from Baseline
NCT04986982 · Phase 4 · registry result, not featured evidence
KPPS Domain 3 -8.7 vs -7.6 placebo score @ 12.14wk50 mg
absolute change · score
Visit 5 (Day 85 (±4)) - Change from Baseline
NCT04986982 · Phase 4 · registry result, not featured evidence
KPPS Domain 3 -8.8 vs -9.3 placebo score @ 24.14wk50 mg
absolute change · score
Visit 6 (Day 169 (±4)) - Change from Baseline
NCT04986982 · Phase 4 · registry result, not featured evidence
MDS-UPDRS Part III -6.5 vs -4.3 placebo score @ 24wk
absolute change · score
NCT04978597 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: entacapone's landscape · Opicapone's landscape